Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1

Etsuko Iio,Noritomo Shimada,Hiroshi Abe,Masanori Atsukawa,Kai Yoshizawa,Koichi Takaguchi,Yuichiro Eguchi,Hideyuki Nomura,Tomoyuki Kuramitsu,Jong-Hon Kang,Takeshi Matsui,Noboru Hirashima,Akihito Tsubota,Atsunori Kusakabe,Izumi Hasegawa,Tomokatsu Miyaki,Noboru Shinkai,Kei Fujiwara,Shunsuke Nojiri,Yasuhito Tanaka

Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1

2017

Background The present study explored the treatment outcome of daclatasvir (DCV) and asunaprevir (ASV) therapy combining oral direct-acting antiviral agents (DAAs) for chronic hepatitis C (HCV) including liver cirrhosis according to resistance-associated variants (RAVs) in NS3/NS5A region.

Keywords:

Cirrhosis
Hepatitis C
Hepacivirus
NS5A
General surgery
Virology
Daclatasvir
NS3
Bioinformatics
Asunaprevir
Simeprevir
Medicine
Diabetes mellitus
Hepatology
Genotype
Internal medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations